More than 3 million bottles of eye drops sold across the United States have been swept up in a sweeping nationwide recall, following a warning from the U.S. Food and Drug Administration (FDA) over concerns that the products may not be sterile. The recall, involving a wide array of over-the-counter eye care products distributed under numerous popular brands and retailers, has left consumers scrambling to check their medicine cabinets and pharmacies working to remove affected stock from shelves.
According to The Economic Times, the recall was initiated by K.C. Pharmaceuticals, Inc., a Pomona, California-based company, on March 3, 2026. The FDA classified the recall as “Class II” on March 31, meaning that while the risk of serious health consequences is considered remote, use of or exposure to the products could cause temporary or medically reversible health problems.
The FDA’s public disclosure of the recall on April 2, 2026, signaled the latest in a series of warnings about eye care products in recent years. The agency’s enforcement report states, “Lack of assurance of sterility” is the core issue, indicating the company cannot guarantee that the manufacturing process prevented the introduction of infection-causing microbes. Importantly, the FDA has not confirmed that any of the bottles were contaminated, but the lack of sterility assurance is enough to prompt the recall of millions of units.
“This classification does not automatically confirm contamination, but suggests that the manufacturer cannot ensure that the products consistently meet sterility standards needed to prevent infection-causing microbes in production,” the FDA noted, as reported by The Economic Times.
The recall affects an eye-popping 3,111,072 bottles of eye drops, distributed under a range of product names and through a long list of major retailers, including Walgreens, CVS, Kroger, H-E-B, Publix, Meijer, Harris Teeter, and even military exchanges, according to Newsweek and FOX Los Angeles. The products are sold under private label brands such as Walgreens, CVS Health, Rite Aid, Leader, Equaline, and more, making it critical for consumers to check not only the brand but the lot number and expiration date.
The list of recalled products is extensive. It includes 182,424 bottles of Sterile Eye Drops AC, 303,216 bottles of Eye Drops Advanced Relief, 1,023,096 bottles of Dry Eye Relief Eye Drops, 245,184 bottles of Ultra Lubricating Eye Drops, 378,144 bottles of Sterile Eye Drops Original Formula, 315,144 bottles of Sterile Eye Drops Redness Lubricant, 74,016 bottles of Sterile Eye Drops Soothing Tears, and 589,848 bottles of Artificial Tears Sterile Lubricant Eye Drops. These figures, provided by Newsweek, reflect the enormous reach of the recall across the U.S. market.
For consumers, the practical advice is clear. The FDA and health experts urge everyone to carefully check the brand, lot number, and expiration date of any eye drops in their possession. Most affected lots have expiration dates extending into May or October 2026, and lot codes may start with AC, AR, LT, SU, RG, RL, SY, or AT. If a match is found, users should stop using the product immediately and either return it to the place of purchase or dispose of it safely.
While the FDA has not provided specific instructions for refunds or replacements, it is expected that major retailers will honor returns or exchanges for the identified lots. “Health authorities advise users to verify product labels and lot numbers carefully, stop using any recalled products immediately, return or dispose of impacted products, and seek medical attention if symptoms such as irritation or vision issues happen,” The Economic Times emphasized.
Anyone who has used these drops and experiences symptoms such as eye pain, redness, or changes in vision should contact an eye doctor or healthcare provider right away, according to FOX Los Angeles. So far, the recall is classified as ongoing and no termination date has been listed in FDA records.
The recall is the latest in a string of high-profile eye product recalls in recent years. Earlier in 2026, another recall was initiated due to the “presence of glass-like particles” in certain eye drops, while in late 2024, the FDA announced a recall after discovering possible fungal contamination that could cause vision damage, as reported by KSNT. Manufacturing practices have come under increased scrutiny as a result, with the FDA stepping up enforcement and inspection efforts in the sector.
But what exactly is a Class II recall? The FDA uses this designation when the use of or exposure to a product may cause temporary or medically reversible adverse health consequences, or when the probability of serious health effects is considered remote. While this is not the most severe category, it still signals a meaningful safety concern that warrants consumer attention and swift action.
Despite the magnitude of the recall, the FDA’s report makes clear that no official press release has been issued by K.C. Pharmaceuticals, Inc. regarding this specific action. Instead, the agency has relied on its enforcement report and public notices to alert both retailers and the general public. The recall is identified under multiple recall numbers, including D-0409-2026 through D-0416-2026, all associated with FDA Event ID 98533, according to Newsweek.
For those looking for more information, the FDA’s enforcement report provides comprehensive details, including lot codes, UPC numbers, and expiration dates, to help consumers determine if their product is impacted. The agency’s website remains the best resource for up-to-date information as the recall process continues.
This episode underscores the importance of quality control in pharmaceutical manufacturing, especially for products like eye drops that are applied directly to sensitive tissues. With more than 3 million bottles affected and a broad range of brands and retailers involved, the recall serves as a stark reminder for both consumers and manufacturers of the need for vigilance when it comes to product safety.
As the recall remains ongoing and with no termination date yet announced, Americans are urged to stay informed, check their medicine cabinets, and consult the FDA’s resources to ensure their eye care products are safe to use. In a landscape marked by recurring recalls and heightened scrutiny, the message from health officials is simple but urgent: when in doubt, check—and if your product is on the list, don’t take chances with your vision.